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The yeast Saccharomyces cerevisiae CDC34 gene en-
codes a ubiquitin-conjugating enzyme that is required
for the cell cycle G1/S transition. We show here that a
dominant negative Cdc34 protein is generated by simul-
taneously replacing both Cys95 and Leu99 with Ser res-
idues. Cys95 is an essential catalytic residue that forms
a transient thiol ester with ubiquitin during catalysis,
and Leu99 is highly conserved among all known ubiq-
uitin-conjugating enzymes. Mutants that encode either
an alanine or a serine at one or both of these two posi-
tions are inactive. Of these eight mutants, overexpres-
sion of CDC34-C95S,L99S in wild type strains was found
to block cell growth. Although cells overexpressing
Cdc34-C95S,L99S do not exhibit the characteristic mul-
tibudded phenotype of cdc34 temperature-sensitive or
null mutants, this blockade is relieved by simultaneous
overexpression of wild type Cdc34. Purified Cdc34-
C95S,L99S protein can be shown to inhibit in vitro ubiq-
uitination of the Cdc34-specific substrate, Cln2 protein.
We suggest that Cdc34-C95S,L99S selectively sequesters
a subset of Cdc34 substrates or regulators. These find-
ings have implications for the structure/function rela-
tionships of ubiquitin-conjugating enzymes, and sug-
gest a general method for identifying components and
substrates of specific ubiquitination pathways of
eukaryotes.
The ubiquitin-conjugating enzymes (E2)1 constitute a family
of conserved proteins that participate either in an intermediate
or in the final step of substrate ubiquitination (Hershko and
Ciechanover, 1992; Finley and Chau, 1991). These enzymes
form a thiol ester adduct with ubiquitin (Ub) in the presence of
ubiquitin-activating enzyme (E1) and ATP in the following
reactions: 1) E1SH 1 Ub 1 ATP7 E1S-Ub 1 AMP 1 PPi, and 2)
E1S-Ub 1 E2SH 7 E1SH 1 E2S-Ub.
Substrate proteins may be directly recognized by an individ-
ual E2 enzyme, resulting in the transfer of ubiquitin from an
E2S-Ub to a lysine on substrate proteins. Alternatively, sub-
strate recognition may require the presence of another group of
proteins known as E3 or ubiquitin-protein ligases (Reiss and
Hershko, 1990; Bartel et al., 1990). A requirement for a specific
E3 protein had been shown for the degradation of substrates in
the N-end rule pathway (Bartel et al., 1990) and for p53
(Scheffner et al., 1993). In the N-end rule pathway, the Ubr1
(E3) protein contains separate sites for Rad6 (E2) and sub-
strate bindings and confers specificity for one of the cellular
Rad6-dependent ubiquitination pathways (Varshavsky, 1992).
In the p53 degradation pathway, it has been further shown
that ubiquitin from E2S-Ub is transferred to a cysteine in the E3
protein (Scheffner et al., 1995), leading to the formation of an
E3S-Ub thiol ester.
CDC34 is one of 10 known ubiquitin-conjugating enzyme-
encoding genes in the yeast, S. cerevisiae (Goebl et al., 1988;
Jentsch, 1992). This gene was initially identified on the basis of
its requirement for cells to undergo the cell cycle G1 to S
transition (Byers and Goetsch, 1973). Under nonpermissive
conditions, temperature-sensitive mutants of CDC34 develop
numerous elongated buds, and the spindle pole body duplicates
but fails to undergo the separation required for spindle forma-
tion (Byers and Goetsch, 1973). More recent studies have es-
tablished a direct role of this ubiquitin-conjugating enzyme in
targeting the degradation of specific regulators of the cell cycle.
Known Cdc34-specific substrates in this category include the
G1 cyclins (Deshaies et al., 1995; Yaglom et al., 1995) and the
Cdc28 kinase inhibitor Sic1 (Schwob et al., 1994). In addition,
mutations in the CDC34 gene can lead indirectly to the abnor-
mal accumulation of other cell cycle regulators such as the
G2-specific B-type cyclins (Amon et al., 1994). Other than its
cell cycle function, the Cdc34-encoded ubiquitin-conjugating
enzyme has also been shown to target the degradation of the
transcription factor GCN4 (Kornitzer et al., 1994), and it is
likely that other functions of this enzyme may be uncovered by
the identification of additional substrate proteins.
The 295-residue Cdc34 protein contains a 170-residue N-
terminal domain that is conserved among all E2 proteins. This
conserved domain is apparently sufficient for E2S-Ub complex
formation since the smallest E2 enzymes are comprised almost
exclusively of this domain (Jentsch, 1992). In Cdc34 this con-
served domain also contains an extra 12-residue sequence near
the ubiquitin-accepting cysteine. This extra sequence is found
only in one other yeast E2 protein, Ubc7 (Jungmann et al.,
1993), and in both cases, the function of this extra sequence
segment remains undefined. In the present study, we report
the effect of mutations at the ubiquitin-accepting cysteine as
well as at Leu99, a residue that is adjacent to this 12-residue
segment. We show here that while both residues are essential
for CDC34 functions, a unique dominant negative allele of this
gene, CDC34DN, could be generated by simultaneously substi-
tuting these two residues with serines. In addition to its poten-
tial utility in genetic analysis, CDC34DN can be used to block
Cdc34-dependent ubiquitination in vitro.
EXPERIMENTAL PROCEDURES
Materials—Ubiquitin was purchased from Sigma. The 125I-labeled
form of ubiquitin was obtained by radioiodination with the use of
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Iodogen (Pierce) according to the manufacturer’s procedure. The spe-
cific activity of 125I-ubiquitin was 5 3 105 cpm/mg. The ubiquitin-
activating enzyme (E1) was purified to homogeneity from calf thymus
as described previously (Ciechanover et al., 1982) and was stored at
280 °C in 20% glycerol. E1 and Cdc34 concentrations were determined
by first converting the proteins to E1S-Ub and Cdc34S-Ub, and the con-
centrations of these thiol esters were estimated from the known specific
radioactivity in [125I]ubiquitin.
Strains of Bacteria and Yeast, Plasmid Vectors, and Genetic Tech-
niques—The bacterial plasmids and phage strains used in this work are
listed in Table I. The S. cerevisiae strains are listed in Table II. All DNA
manipulations were done according to Sambrook et al. (1989). Plasmid
vectors that expressed Cdc34 from the galactose-inducible PGAL1 pro-
moter were constructed using the vectors YEplac195 and YIplac211
(Gietz and Sugino, 1988) by isolating a ;0.7-kilobase BamHI-EcoRI
fragment of pG12 that contained the PGAL1/GAL10 promoter region
(Johnston and Davis, 1984) and ligating the fragment into the high copy
(2m-based) plasmids YEplac195 and YEplac181, and integrating plas-
mid YIplac211, yielding plasmid vectors YEp195GAL, YEp181GAL,
and YIp211GAL. Fragments of ;0.9 kilobase encoding CDC34 and its
mutants (without the native promoter) bordered by SalI and SphI sites
(Banerjee et al., 1993) were then ligated into the SalI- and SphI-cut
YEp195GAL and YIp211GAL, yielding various constructs used in this
study. CDC34 was also cloned into the YEp181GAL vector. Proper
induction by galactose of Cdc34 and mutant proteins for each of the
yeast strains integrated/transformed with these plasmids was checked
by immunoblotting with anti-Cdc34 polyclonal antibodies.
Growth and Induction of Yeast Strains—The S. cerevisiae strains
used in this work were grown at 30 °C (332 derivatives) or 23 °C
(MGG15 derivatives) in rich (YPD) or synthetic media (Sherman et al.,
1986), with the latter containing 2% dextrose (SD medium), 2% raffi-
nose (SR medium), or 2% galactose (SG medium). Transformation/
integration of S. cerevisiae was carried out by the methods of Sherman
et al. (1986) or Shiestel and Gietz (1989). For galactose induction of
yeast strains, cells were first grown to A600 of ;0.1 in SR medium
lacking uracil (and relevant amino acids when necessary), and galac-
tose was added to a final concentration of 2%. Samples were withdrawn
at time points described under “Results” and processed.
Construction of CDC34 Mutants—The CDC34 mutants were con-
structed by site-directed mutagenesis of the CDC34 gene in M13 mp19
(Banerjee et al., 1993). The Cys95 TGT codon was changed to either a
TCT for Ser or a GCT for Ala. The Leu99 TTA codon was changed to
either a TCA for Ser or a GCA for Ala. These changes were made by the
procedure of site-specific mutagenesis (Taylor et al., 1985) with an
Amersham mutagenesis kit. DNA sequencing by the chain termination
method (Sanger et al., 1977) was used to verify all constructs. The
CDC34-C95S,L99S sequence was also inserted into the lPL-promoter-
based plasmid as described previously for the wild type CDC34 gene
(Banerjee et al., 1993), resulting in the plasmid pLlCDC34-C95S,L99S.
Expression of Cdc34, Cdc34-C95S,L99S, and Rad6 Proteins in
Escherichia coli and Their Purification—The plasmids pNMCDC34
(Banerjee et al., 1993) and pLlCDC34-C95S,L99S were transformed
into E. coli host AR58, which contains a temperature-sensitive l re-
pressor. These cells, harboring pNMCDC34 and pLlCDC34-C95S,L99S
plasmids, were grown at 30 °C to a density of 1 absorbance unit at 600
nm. The culture (2 liters) was shifted to 42 °C for 2 h and incubated
for an additional 3 h at 39 °C. An SDS gel analysis of proteins in crude
E. coli extracts revealed the induction of Cdc34 as a major protein.
The proteins were purified according to previously published protocols
(Banerjee et al., 1993). Rad6 was purified from E. coli extracts that had
the protein overexpressed from the RAD6 gene cloned in pKK223–3
vector (Haas et al., 1991).
Expression of M13 mp19-CDC34 Mutant Genes—To express Cdc34
mutant proteins, individual mutant genes in M13 mp19/18 were used to
infect a 1:500 dilution of an overnight culture of E. coli host TG1 in LB
to obtain a multiplicity of infection of 30–40. After 3 h of growth at
37 °C, the medium was adjusted to contain 1 mM isopropyl-1-thio-b-D-
galactopyranoside, and incubation was continued for an additional 2 h.
Cells from 3-ml cultures were harvested by centrifugation, washed with
50 mM Tris (pH 7.5), and suspended in 100 ml of the same buffer and 0.5
mM dithiothreitol. Cells were lysed by sonication for 30 s at 30 watts,
and after 5 min of centrifugation at 12,000 rpm in an Eppendorf cen-
trifuge, the supernatant was used to assay for ubiquitin thiol ester and
conjugate formation in a final reaction volume of 20 ml using standard
reaction conditions. The amounts of Cdc34 and mutant proteins were
determined and normalized by immunoblotting using the ECL (Amer-
sham Corp.) method of detection. Incubation times of 15 and 45 min
were used in thiol ester and Ub-Cdc34 complex formation, respectively.
Cdc34S-Ub and Ub-Cdc34 Complex Formation—Reactions were car-
ried out in 50 mM Tris (pH 7.5), 10 mM MgCl2, 2 mM ATP, 50 mM
dithiothreitol, and 5 mM ubiquitin at 30 °C. Unless stated otherwise, 50
nM of E1 (from calf thymus) and 100 nM of Cdc34 or its mutant proteins
were used in the reactions. The amounts of Cdc34 and mutant Cdc34
proteins in the assay were determined by quantitation with Cdc34-
specific antibodies using the Amersham ECL detection method and
purified Cdc34 standards. Reactions were stopped by withdrawing ali-
quots of the reaction mixture into SDS-sample buffer in which b-mer-
captoethanol had been omitted. When Ub-Cdc34 complexes were as-
sayed, protein samples were adjusted to contain 5% b-mercaptoethanol,
and samples were heated in a boiling water bath for 3 min. Protein
samples were subjected to electrophoresis in a 14% SDS-polyacrylamide
gel, and autoradiography was used to visualize radiolabeled bands.
Preparation of Polyclonal Anti-Cdc34 Antibodies and Western Blot
Analysis—Anti-Cdc34 antiserum was prepared in New Zealand White
rabbits using the recombinant Cdc34 protein produced and purified by
the method of Banerjee et al. (1993). Immunization and antibody proc-
essing techniques were done according to the protocols of Harlow and
Lane (1988). For visualization and determination of the amount of
Cdc34 protein, yeast cells were harvested by centrifugation, washed
once with 50 mM Tris-HCl buffer, pH 7.5, 1 mM dithiothreitol, and
resuspended in 200 ml of breakage buffer (50 mM Tris-HCl, pH 7.5, 1 mM
dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 2 mg/ml leupeptin,
and 2 mg/ml pepstatin A). Cells were broken by vortexing with glass
beads. A 100-ml aliquot of 3 3 PAGE sample buffer (without b-mercap-
toethanol) was added, and the mixture was immediately boiled for 3
min. The glass beads and cell debris were removed by centrifugation. A
10-ml aliquot was removed for protein assay by Pierce BCA reagent, and
the remainder of the sample was adjusted to contain 5% b-mercapto-
ethanol. Cell extracts containing equal amounts of protein (300 mg)
were electrophoresed on a 15% SDS-PAGE gel (Laemmli, 1970). Pro-
teins were transferred to polyvinylidene difluoride membrane and vi-
sualized by reaction with anti-Cdc34 polyclonal antibodies by protocols
described by Harlow and Lane (1988). The enhanced chemiluminis-
cence (ECL) kit was purchased from Amersham Corp. and used accord-
ing to their instructions. Alkaline phosphatase-conjugated anti-rabbit
IgG was purchased from Sigma, and color reaction was done according
TABLE I
Bacterial phages and plasmids
Plasmid/phage Genotype/description Source/reference
M13mp19/M13mp18 Cloning vectors Yanisch-Perron et al. (1985)
M13mp19CDC34 CDC34 with lac promoter Banerjee et al. (1993)
M13mp19CDC34-C95S,L99S CDC34-C95S,L99S with lac promoter This study
M13mp19cdc34-L99S cdc34-L99S with lac promoter This study
M13mp19cdc34-L99A cdc34-L99A with lac promoter This study
M13mp18cdc34-C95S cdc34-C95S with lac promoter This study, derivative of plasmid
pYLC95S from M. Goebl
M13mp19cdc34-C95S,L99A cdc34-C95S,L99A with lac promoter This study
M13mp19cdc34-C95A cdc34-C95A with lac promoter This study
M13mp19cdc34-C95A,L99S cdc34-C95A,L99S with lac promoter This study
M13mp19cdc34-C95A,L99A cdc34-C95A,L99A with lac promoter This study
pNMCDC34 CDC34 with lpL promoter Banerjee et al. (1993)
pLlCDC34-C95S,L99S CDC34-C95S,L99S with lpL promoter This study
pRD68 CLN2 with T7 promoter Deshaies et al. 1995
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to Blake et al. (1984).
Analysis of Cln2 Multiubiquitination—Expression of Cln2 in vitro
was achieved by inserting a BamHI fragment containing the CLN2
gene into the BamHI site of pGEM2, yielding pRD68, where the CLN2
gene could be transcribed by the T7 promoter (Deshaies et al., 1995).
This RNA was used for in vitro translation by the rabbit reticulocyte
lysate system. Reagents for the in vitro translation were obtained from
Promega Biotech. [35S]Cln2 synthesized in vitro was incubated in 15
mg/ml pRD84/RD205–3A extract. Reactions were supplemented with
;1 mM Cdc28 (Deshaies et al., 1995) and the indicated amounts of Cdc34
or Cdc34-C95S,L99S, all purified from E. coli. Reactions were directly
evaluated by SDS-PAGE and fluorography.
RESULTS
Overexpression of Cdc34-C95S,L99S Inhibits Cell Growth—
The S. cerevisiae CDC34 gene encodes a ubiquitin-conjugating
enzyme that is required for the cell cycle G1/S transition (Byers
and Goetsch, 1973). The yeast strain MGG15 contains a tem-
perature-sensitive cdc34–2 allele, and these cells are inviable
at nonpermissive temperatures (Goebl et al., 1988). In the
course of using MGG15 cells to determine the functional com-
petence of several CDC34 site-specific mutants, we noted that
MGG15 cells failed to form colonies even at permissive temper-
atures when these cells are also expressing a CDC34-
C95S,L99S mutant via a galactose-inducible promoter in a 2m
plasmid (Fig. 1A). In contrast, similar expression of the two
singly substituted mutants, cdc34-C95S and cdc34-L99S, did
not affect the viability of MGG15 cells. CDC34-C95S,L99S is
likely to encode an inactive protein since the singly substituted
mutants, cdc34-C95S and cdc34-L99S, each failed to comple-
ment the temperature-sensitive growth defect of MGG15 cells
(data not shown).
To test whether the dominant effect of CDC34-C95S,L99S
mutant is uniquely dependent on the cdc34–2 allele, we also
introduced this mutant gene into a yeast strain that carries a
wild type CDC34 allele. The ABY100 strain contains an inte-
grated copy of CDC34-C95S,L99S whose expression is regu-
lated by the PGAL1 promoter (Table II). These cells also failed to
grow on galactose medium (Fig. 1B) and became inviable (data
not shown). These results indicate that the dominant effect of
CDC34-C95S,L99S on cell growth and viability is not restricted
to the cdc34–2 strain. Similar expression of the singly substi-
tuted mutants, cdc34-C95S and cdc34-L99S, did not alter cell
viability (data not shown).
Since the unique effect of the CDC34-C95S,L99S mutant
may be due to its higher level of accumulation than those of the
FIG. 1. Effect of CDC34-C95S,L99S expression in yeast cells.
Panel A, effect of CDC34-C95S,L99S expression in MGG15 (Table II)
cells carrying ts-cdc34–2 at the permissive temperature of 23 °C.
ABY210 (cdc34–2 1 YEpGALCDC34), ABY214 (cdc34–2 1 YEpGAL-
cdc34-L99S), ABY216 (cdc34–2 1 YEpGALcdc34-C95S), and ABY212
(cdc34–2 1 YEp GALCDC34-C95S,L99S were grown to an A600 of 0.2 in
SR medium at 23 °C and streaked in duplicate onto medium containing
galactose. Panel B, the GAL1-CDC34-C95S,L99S mutant was inte-
grated into wild type yeast strain 332 (ABY100). Similarly integrated
GAL1-CDC34 resulted in ABY200 (Table II). Spot assays were done to
compare the viability of ABY100 and ABY200 cells upon galactose-
induced expression of CDC34 and CDC34-C95S,L99S alleles. ;25,000
cells (grown in SR medium to an A600 of 0.2, and counted by hemocy-
tometer) were spotted in the first spot on each panel. The next two spots
in each panel are two successive 10-fold dilutions. Plates were incu-
bated at 30 °C. ABY200 (URA3::GALCDC34) spots in galactose medium
show no deleterious effect or loss in viability, whereas ABY100
(URA3::GALCDC34-C95S,L99S) spots in galactose medium show lethal




Name Relevant markers/plasmids Source/Comment
332 Mata ura3–52 leu2 his3 R. Needleman
ABY200 Mata URA3::GALCDC34 leu2 his3 This study, derivative of 322
ABY100 Mata URA3::GALCDC34-C95S,L99S leu2 his3 This study, derivative of 322
ABY102 Mata URA3::GALCDC34-C95S,L99S leu2 his3 1
YEp181GALCDC34
This study derivative of ABY100
ABY110 Mata URA3::GALcdc34-L99S leu2 his3 This study, derivative of 322
ABY120 Mata URA3::GALcdc34-L99A leu2 his3 This study, derivative of 322
ABY130 Mata URA3::GALcdc34-C95S leu2 his3 This study, derivative of 332 and
plasmid pYLC95S from M.
Goebl
ABY140 Mata URA3::GALcdc34-C95S,L99A leu2 his3 This study, derivative of 322
ABY150 Mata URA3::GALcdc34-C95A leu2 his3 This study, derivative of 322
ABY160 Mata URA3::GALcdc34-C95A,L99S leu2 his3 This study, derivative of 322
ABY170 Mata URA3::GALcdc34-C95A,L99A leu2 his3 This study, derivative of 322
MGG15 Mata cdc34–2 ura3 his3 M. Goebl
ABY210 Mata cdc34–2 ura3 his3 1 YEp195GALCDC34 This study, derivative of MGG15
ABY212 Mata cdc34–2 ura3 his3 1 YEp195GALCDC34-
C95S,L99S
This study, derivative of MGG15
ABY214 Mata cdc34–2 ura3 his3 1 YEp195GALcdc34-L99S This study, derivative of MGG15
ABY216 Mata cdc34–2 ura3 his3 1 YEp195GALcdc34-C95S This study, derivative of MGG15
pRD84/RD205–3A cln1D, cln2::LEU2, cln3D, trp1, leu2, ura3,
pep4::LEU2 1 [GAL-CLN3, URA3, CEN, ARS]
Deshaies et al. (1995)
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singly substituted mutants, cdc34-C95S and cdc34-L99S, we
also used immunoblotting to assess the level of mutant proteins
in cells expressing these various mutant genes. Immunoblots of
Cdc34 proteins from cells before and after 2 or 8 h of induction
in galactose indicated that the Cdc34-C95S,L99S protein did
not accumulate to a higher level than the other mutants (data
not shown). Thus, the unique effect of Cdc34-C95S,L99S on cell
viability is not due simply to the overexpression of an inactive
Cdc34 protein.
CDC34-C95S,L99S Acts on the Same Pathway as CDC34—
Immunoblots, probed with ubiquitin-specific antibodies,
showed that the expression of CDC34-C95S,L99S, cdc34-C95S,
and cdc34-L99S mutants did not cause detectable changes in
the overall level of ubiquitin-protein conjugates (data not
shown). However, two lines of evidence indicated that CDC34-
C95S,L99S affects cell viability by disruption of CDC34-de-
pendent protein ubiquitination. First, the effect of CDC34-
C95S,L99S in ABY100 cells was suppressed by the
concomitant expression of wild type CDC34 via either its nat-
ural promoter or a galactose-inducible promoter in 2m plasmids
(data not shown). Similar plasmids carrying either the singly
substituted cdc34-C95S or cdc34-L99S mutant did not restore
growth of ABY100 cells on galactose medium (data not shown).
Second, purified Cdc34-C95S,L99S protein inhibited the in
vitro ubiquitination of the G1 cyclin Cln2, a reaction that has
recently been shown to require Cdc34 (Deshaies et al., 1995).
Yeast extract derived from wild type CDC34 cells catalyzes the
ubiquitination of Cln2 obtained by in vitro translation in re-
ticulocyte lysate (Deshaies et al., 1995; Fig. 2, lane 2). This
reaction could be further stimulated by the addition of purified
Cdc34 protein (Fig. 2, lane 3). Ubiquitination of this substrate
was inhibited by additions of purified Cdc34-C95S,L99S pro-
tein in a dose-dependent manner (Fig. 2, lanes 4 and 5).
The inhibition of Cln2 protein ubiquitination is not due to
general inactivation of ubiquitin conjugation pathways since
the overexpression of this mutant protein did not affect ubiq-
uitin conjugation to other endogenous proteins (Fig. 3A). We
have also assayed the effect of Cdc34-C95S,L99S on purified
ubiquitin-activating enzyme by monitoring the catalytic trans-
fer of ubiquitin from the ubiquitin-activating enzyme to an-
other yeast ubiquitin-conjugating enzyme, Rad6 (Fig. 3B). As
shown in Fig. 3B, the level of ubiquitin-Rad6 thiol ester was not
detectably affected by 2–20 mM of Cdc34-C95S,L99S. These
results, taken together, indicate that Cdc34-C95S,L99S inhib-
its Cln2 ubiquitination via specific inhibition of the Cdc34-de-
pendent pathway.
While the above results indicated that CDC34-C95S,L99S
exerts its effect by interfering with an essential CDC34-de-
pendent process, cells overexpressing this mutant did not ex-
FIG. 2. Inhibition of Cln2 multiubiquitination by Cdc34-
C95S,L99S. [35S]Cln2 was synthesized in vitro in the reticulocyte ly-
sate system and was incubated in 15 mg/ml yeast extract for 0 (lane 1)
or 60 (remaining lanes) min. at 24 °C in the presence of the indicated
amounts of Cdc34 or Cdc34-C95S,L99S (see “Experimental Proce-
dures”). Lane 2 has the reaction incubated without exogenous Cdc34.
Lane 3 has the reaction supplemented with 180 nM of wild type Cdc34.
The reaction in lane 4 had 180 nM, and that in lane 5 had 540 nM of
Cdc34-C95S,L99S added. Cln2, unphosphorylated Cln2 with a molecu-
lar mass of ;66 kDa; PP-Cln2, hyperphosphorylated Cln2 with a mo-
lecular mass of ;84 kDa; Ub-Cln2, multiubiquitinated Cln2.
FIG. 3. Ubiquitin-activating enzyme is not affected by overex-
pression of the CDC34-C95S,L99S. Panel A, extracts were prepared
from 10-h galactose-induced ABY200 (URA3::GALCDC34), and
ABY100 (URA3::GALCDC34-C95S,L99S) in breakage buffer; ;300 mg
of total protein in 60 ml volume was supplemented with 200 ng of
125I-Ub and incubated at 30 °C for 30 min. 30 ml of 3 3 SDS-PAGE
sample buffer was added, samples were boiled for 3 min, and the
reactions were analyzed by 14% Laemmli gels. Lanes 1 and 3, ABY100
reaction at 10 and 30 min; lanes 2 and 4, ABY200 reaction at the same
time points. The radioactive protein ladder indicating ubiquitination of
yeast proteins is similar in intensity and pattern for extracts from both
of these cell types. The positions of Life Technologies, Inc. prestained
high molecular mass markers (myosin, 215 kDa; phosphorylase B, 105
kDa; bovine serum albumin, 70 kDa; ovalbumin, 43 kDa; carbonic
anhydrase, 29 kDa; b-lactoglobulin, 18 kDa; and lysozyme, 14 kDa) are
marked on the left. Panel B, formation of Rad6S-Ub thiol ester complexes
was assayed by incubation with 250 nM purified Rad6 protein and
indicated amounts of Cdc34-C95S,L99S protein with ubiquitin-activat-
ing enzyme (E1), magnesium, ATP, and 125I-ubiquitin for 20 min at
30 °C. The reaction products were electrophoresed in a 14% SDS gel in
the absence of thiol-reducing agents, and radiolabeled proteins were
visualized by autoradiography.
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hibit the morphological phenotype of previously characterized
loss-of-function mutants. The cdc34 null mutant strain, as well
as the temperature-sensitive cdc34–1 and cdc34–2 strains ar-
rest as multibudded cells (Goebl et al., 1988). This morphology
is absent in ABY100 cells that assume aberrant morphology
after switching cells to a galactose-containing medium. A ma-
jority of these aberrant cells were found to have a single elon-
gated bud (data not shown). The absence of multibudded cells
is not due to a strain difference since MGG15 cells that are
overexpressing Cdc34-C95S,L99S also took on, at both permis-
sive and nonpermissive temperatures for cdc34–2, morpholo-
gies similar to those of ABY100 cells in galactose (data not
shown). This difference in morphology is consistent with the
notion that Cdc34-C95S,L99S does not simply inactivate en-
dogenous wild type Cdc34 protein. Possible mechanisms of
Cdc34-C95S,L99S action are described further under
“Discussion.”
The Role of Cys95 and Leu99 in Cdc34-C99S,L99S—Since
neither cdc34-C95S nor cdc34-L99S affects cell viability, it
appears that both mutations must be present to confer the
dominant negative phenotype. Cys95 is expected to be an
essential residue since it is the only cysteine in the Cdc34
protein, and the presence of this amino acid is required for all
ubiquitin-conjugating enzymes to form a thiol ester complex
with ubiquitin. Leu99 is a highly conserved residue among
ubiquitin-conjugating enzymes, and the inability of cdc34-
L99S to complement cdc34–2 suggests that this residue is also
essential. We have also generated a set of mutants in which
Cys95 and Leu99 were replaced by alanines or by alanine/serine
pairs. None of these mutants was able to complement cdc34–2
(data not shown), suggesting that these two residues are indeed
essential. We also constructed yeast strains with wild type
CDC34 that had an integrated copy of these mutant genes
under the control of a PGAL1 promoter (ABY110, ABY120,
ABY130, ABY140, ABY150, ABY160, and ABY170 in Table II)
and tested their effect on cell growth. Unlike CDC34-
C95S,L99S, none of these mutants was found to block cell
growth (data not shown). These results suggest that the dom-
inant negative effect may have a stringent requirement for
serines at these two residue positions.
The requirement for a serine at the Cys95 residue may be due
to the unique ability of a serine to form a more stable linkage
with ubiquitin (Sung et al., 1991). In a normal ubiquitin-con-
jugating enzyme, the active site cysteine forms a thiol ester
linkage with the C-terminal carboxyl of ubiquitin. This thiol
ester-linked ubiquitin is subsequently transferred either to a
E3 protein or to substrates directly. Substitution of the active
site cysteine by a serine has been shown to inactivate other
ubiquitin-conjugating enzymes (Sung et al., 1991; Seufert et al.,
1995) presumably because the more stable oxygen ester-linked
ubiquitin is not further transferred. In the case of Cdc34, we
have previously shown that the thiol ester-linked ubiquitin can
also be transferred to a lysine within this enzyme in an in-
tramolecular reaction to form a Lys48-specific multiubiquitin
chain (Banerjee et al., 1993). This autoubiquitination reaction
was used here to test the effect of Cys95 substitution. For these
experiments, the cdc34 mutants were expressed in E. coli and
assayed for their ability to accept [125I]ubiquitin in the pres-
ence of added ubiquitin-activating enzyme (Fig. 4). Under our
assay conditions, the reaction with wild type Cdc34 leads to
products that migrated as a set of discrete bands on SDS gels
(Fig. 4A, lane 1). These discrete bands are due to the linkage of
multiple ubiquitin groups, in the form of a ubiquitin chain, to a
lysine residue in Cdc34 (Banerjee et al., 1993). In contrast, only
a single ubiquitin-Cdc34 adduct was detected with the mutants
Cdc34-C95S, Cdc34-C95S,L99A, and Cdc34-C95S,L99S. This
single adduct was not present in any of the C95A-substituted
mutants, consistent with the notion that this single adduct is
due to the linkage of ubiquitin to the substituted serine at
position 95. The absence of additional adducts of lower electro-
phoretic mobilities in these C95S-substituted mutants indi-
cates that autoubiquitination did not occur with these mutants.
These results indicate that the C95S-substituted cdc34 mu-
tants can indeed form a more stable oxygen ester with ubiq-
uitin and raise the possibility that the effect of CDC34-
C95S,L99S on cell viability may require the linkage of
ubiquitin to Ser95.
We have also monitored the formation of ubiquitin-Cdc34
thiol ester with shorter reaction time (15 min), using a nonre-
ducing SDS gel (Fig. 4B, lanes 1–3). Both Cdc34-L99S and
Cdc34-L99A were found to retain partial activity as indicated
by the presence of a 42-kDa radiolabeled band that corresponds
to ubiquitin-Cdc34 thiol ester. This result indicated that unlike
FIG. 4. Formation of Ub-Cdc34 complexes by the mutant Cdc34
proteins. Panel A, Cdc34 or its mutants were expressed in E. coli
harboring the appropriate M13 mp19/18-CDC34 constructs (see “Ex-
perimental Procedures”). Amounts of the recombinant protein in the
bacterial extracts were normalized for the assays. Thiol-insensitive
Ub-Cdc34 complexes were assayed by incubating E. coli extracts with
;100 nM overexpressed Cdc34 or its mutant proteins with ubiquitin-
activating enzyme, magnesium, ATP, and 125I-ubiquitin for 45 min.
Samples were adjusted to contain 5% b-mercaptoethanol and heated at
90 °C for 3 min prior to SDS-PAGE. The uppermost band corresponds to
ubiquitin linked to a lysine on E1. The ladder bands with the wild type
Cdc34 are due to the linkage of a multiubiquitin chain to a lysine on
Cdc34 (Banerjee et al., 1993). The single band with the C95S mutants
is presumably due to the formation of a Ub-Cdc34 oxygen-ester at
Cdc34-Ser95 (position indicated by arrow on the right). Panel B, forma-
tion of Cdc34S-Ub thiol ester complexes was assayed by incubating E.
coli extracts with ;100 nM overexpressed Cdc34 or its mutant proteins
with ubiquitin-activating enzyme, magnesium, ATP, and [125I]ubiquitin
as in panel A, except the reaction time was reduced to 15 min. The
reaction products were electrophoresed in a 14% SDS gel in the absence
of thiol-reducing agents, and radiolabeled proteins were visualized by
autoradiography. Open arrow indicates Ub-Cdc34 complex; closed ar-
row indicates E1S-Ub complex.
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mutations at Cys95, mutants of Leu99 are inactive at a step
subsequent to ubiquitin-thiol ester formation. Thus, mutations
at Leu99 appear to interfere with Cdc34 interactions with ei-
ther substrate or E3 protein(s). Interestingly, a higher activity
was found for the L99S-substituted mutant than the L99A
mutant. Similarly, the shorter reaction time also revealed a
faster ubiquitin linkage to Ser95 in Cdc34-C95S,L99S as com-
pared with Cdc34-C95S and Cdc34-C95S,L99A (Fig. 4B, lanes
4, 9, and 5, respectively). Whether this difference in reactivity
could account for the stringent requirement for the L99S sub-
stitution remains to be determined.
DISCUSSION
The ability of Cdc34-C95S,L99S to inhibit the cell cycle func-
tion of CDC34 is indicated by its in vivo effect on cell viability
and by its in vitro effect on Cln2 ubiquitination. Proteins that
are known to be targeted by Cdc34 for ubiquitin-mediated
proteolysis include G1 cyclins (Deshaies et al., 1995, Yaglom et
al., 1995), the yeast transcription factor GCN4 (Kornitzer et al.,
1994) and the Cdc28 kinase inhibitor Sic1 (Schwob et al., 1994).
Since overexpression of Cln2 does not lead to cell inviability
(Lew and Reed, 1993), it is likely that Cdc34-C95S,L99S also
inhibits the degradation of other Cdc34-dependent substrates.
One likely candidate is Sic1, which is normally degraded prior
to cell entry into the S phase (Schwob et al., 1994), and a
moderate overexpression of this protein has previously been
shown to produce cellular morphology (Nugroho and Menden-
hall, 1994) similar to those found for cells overexpressing
Cdc34-C95S,L99S. Consistent with this notion is the recent
demonstration that the human homolog of Cdc34-C95S,L99S
could also inhibit Cdc34-dependent degradation of the cyclin-
dependent kinase inhibitor, p27 (Pagano et al., 1995). The
ability of Cdc34-C95S,L99S to inhibit the in vitro ubiquitina-
tion and/or degradation of two dissimilar substrates in two
different species raises the possibility that this mutant may be
used in analogous manner to establish the identity of addi-
tional Cdc34-specific substrates.
Cells expressing Cdc34-C95S,L99S exhibit a morphology
that differs significantly from the multibudded morphology of
previously characterized loss-of-function cdc34 mutants. A sig-
nificant proportion of these cells contain a single, elongated
bud, while multibudded cells are conspicuously absent. As the
mechanism for multibudding in the cdc34 null mutant has not
been defined, the morphological difference here could not be
readily addressed. Nonetheless, this difference suggests that
the effect of Cdc34-C95S,L99S is not equivalent to a straight-
forward loss of CDC34 functions. Previous studies have indi-
cated that Cdc34 is capable of self association, and this process
requires a region in the sequence that is apparently essential
for its cell cycle function (Ptak et al., 1994). Conceivably,
Cdc34-C95S,L99S could exert its effect by sequestering endog-
enous Cdc34. However, this mechanism is incompatible with
the absence of multibudded cells. Furthermore, the effect of
Cdc34-C95S,L99S could not be obtained with the other seven
inactive cdc34 mutants that contain the same determinant for
self-association. In addition, we have obtained preliminary re-
sults indicating that purified Cdc34-C95S,L99S does not in-
hibit a previously characterized in vitro autoubiquitination of
Cdc34 (Banerjee et al., 1993) or the conjugation of ubiquitin to
histone proteins (Haas et al., 1991). Thus, it is unlikely that the
effect of Cdc34-C95S,L99S is due to the sequestration of endog-
enous Cdc34.
Since Cdc34-C95S,L99S encodes an inactive ubiquitin-con-
jugating enzyme, the mechanism of inhibition is likely to reside
in a binding step where this mutant could compete effectively
with Cdc34. A key unanswered question here is whether sub-
strate recognition in this pathway also requires E3 proteins. A
requirement for E3 has been shown for several other ubiquiti-
nation pathways. For example, the Ubr1 protein is required in
the N terminus rule pathway (Bartel et al., 1990), and a protein
known as E6AP is required for the ubiquitination of p53 (Schef-
fner et al., 1993). The ubiquitination of mitotic cyclins appears
to require a large protein complex consisting of several distinct
proteins (Sudakin et al. (1995); reviewed in Murray (1995)).
Thus, the effect of Cdc34-C95S,L99S could result from the
sequestration of Cdc34-specific substrates or the required E3
protein(s).
Cys95 and Leu99 are located within a sequence region that is
highly conserved among ubiquitin-conjugating enzymes. This
conserved sequence region has been termed the catalytic core
domain and is conserved in tertiary folding as shown by the
crystal structures of Arabidopsis thaliana Ubc1 and Saccharo-
myces cerevisiae Ubc4 (Cook et al., 1993). A structural model of
the Cdc34 catalytic core could be constructed by aligning resi-
dues 10–100 of Cdc34 with the N-terminal 91 residues of Ubc4.
FIG. 5. Panel A, model of the ternary
complex formation between E3 and
E2S-Ub ubiquitin-E2 thiol ester complex
docks on an E3 by noncovalent interac-
tions to form II. Both ubiquitin and E2
contribute to the stability of II. Transthio-
lation (Scheffner et al., 1995) leads to the
attachment of ubiquitin to a cysteine in
E3, and ubiquitin no longer contributes to
the retention of E2 in the ternary complex
III. In the case of Ub-Cdc34-C95S,L99S
oxygen ester, ubiquitin is not transferred
to E3, leading to the sequestration of E3
in an inactive complex. Panel B, align-
ment of the Cdc34 catalytic site sequence
with other ubiquitin-conjugating enzyme
sequences. The yeast Cdc34 (Goebl et al.,
1988) sequence is aligned with those of
human Cdc34 (Plon et al., 1993), yeast
Ubc7 (Jungmann et al., 1993), Rad6
(Jentsch et al., 1987), and Ubc4 (Seufert
and Jentsch, 1990) to show the position-
ing of the 12/13-residue segment in Cdc34
and Ubc7. Positions of mutant residues in
Cdc34-C95S,L99S are indicated below by
closed circles. The starting and end resi-
due numbers for each sequence in the
alignment are given in parentheses.
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Both Cys95 and Leu99 could be placed within this structural
model at positions that are occupied by identical amino acids in
Ubc4. In this model, substitution of Cys95 by either alanine or
serine would not introduce other structural perturbations.
Thus, the difference between Cdc34-C95S,L99S and Cdc34-
C95A,L99S is unlikely to be structural but rather in the ability
of Ser95 to form a stable oxygen ester with ubiquitin. This
suggests that the inhibitory effect of Cdc34-C95S,L99S may
require prior formation of the ubiquitin-Cdc34-C95S,L99S
ester.
A model that could account for the inhibitory effect of Cdc34-
C95S,L99S is depicted in Fig. 5A. In this model, ubiquitin
contributes partly to the energetics of the ternary complex
formation between the ubiquitin-E2 thiol ester and E3. Once
ubiquitin has been transferred to E3, the ubiquitin-conjugating
enzyme would presumably bind less tightly since it is no longer
linked to ubiquitin. The reduced affinity may then facilitate the
dissociation of the ubiquitin-conjugating enzyme, which could
be recharged with ubiquitin by the ubiquitin-activating enzyme
(E1). The existence of a ubiquitin binding site on E3 is sup-
ported by studies on a reticulocyte E3 in the N-end rule path-
way (Reiss and Hershko, 1990). This model makes the predic-
tion that E2 mutants containing a stably linked ubiquitin
would be better inhibitors than inactive enzymes that cannot
be linked with ubiquitin and explains the unique requirement
for the C95S mutation. The requirement for the L99S mutation
could be explained by the observation that this mutation causes
ubiquitin to be linked to Ser95 at a faster rate (Fig. 4). A
structural basis of this effect could not be readily assessed
using the two known structures of E2 enzymes since Cdc34
contains an extra 12-residue segment beginning at residue 101,
and this extra segment could not be accommodated in a struc-
tural model. A similar sequence segment is also present in the
yeast Ubc7 protein (Fig. 5B), and the crystal structure of this
ubiquitin-conjugating enzyme has recently been determined,2
and work is in progress to determine the mutational effect of
the corresponding leucine residue in this enzyme.
Dominant negative mutants in other yeast genes have
proved useful for the identification of interacting proteins via
suppresser analyses. If the action of Cdc34-C95S,L99S depends
on its interaction with E3 proteins, one class of suppressers is
expected to be comprised of these proteins. The ability of puri-
fied Cdc34-C95S,L99S to block the in vitro ubiquitination of
Cln2 suggests a further utility of this mutant for the identifi-
cation of additional Cdc34-specific substrates. Although sub-
strates in a specific ubiquitin-dependent pathway could usually
be identified in yeast by showing their increased stability in a
specific ubc mutant, this approach may be insufficient to pro-
vide unambiguous identification of CDC34-specific substrates.
For example, while the G2-specific B-type cyclins are stabilized
in CDC34 mutants (Amon et al., 1994), degradation of these
cyclins is apparently mediated by UBC9 (Seufert et al., 1995),
and the effect of cdc34 in this case could be attributed to the
abnormal accumulation of Cln proteins in cdc34 mutants.
Thus, an unambiguous identification of a CDC34-specific sub-
strate may also require the use of in vitro approaches to dem-
onstrate a direct requirement of this ubiquitin-conjugating en-
zyme. One such approach may be by using the Cdc34-
C99S,L99S mutant protein to inhibit the ubiquitination or the
degradation of a candidate substrate protein in a cell-free sys-
tem. This approach has been used recently to help in establish-
ing a role of Cdc34 in degradation of the human cyclin-depend-
ent kinase inhibitor, p27. Dominant negative mutants of yeast
UBC genes could be readily identified by genetic screens. The
creation of an analogous dominant negative mutant of human
Cdc34 with mutations identified in the yeast enzyme points to
the important possibility that other dominant negative mu-
tants of mammalian ubiquitin-conjugating enzymes could be
obtained by a similar approach. Such mutants could then be
used for exploring substrates and/or regulators of protein ubiq-
uitination in mammalian systems.
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